Profile data is unavailable for this security.
About the company
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
- Revenue in EUR (TTM)45.17bn
- Net income in EUR6.22bn
- Incorporated1994
- Employees84.59k
- LocationSanofi SA46 Avenue de la Grande ArmeePARIS 75017FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Blueprint Medicines Corp | -5.03% | 9.10bn |
| Vigil Neuroscience Inc | -11.12% | 466.72m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zoetis Inc | 8.01bn | 2.17bn | 57.60bn | 13.80k | 26.94 | 14.38 | 22.13 | 7.19 | 5.57 | 5.57 | 20.54 | 10.44 | 0.6529 | 1.07 | 7.00 | 672,898.60 | 17.77 | 15.25 | 21.83 | 18.31 | 70.98 | 70.18 | 27.22 | 26.32 | 1.04 | 21.14 | 0.5856 | 28.93 | 8.33 | 8.14 | 6.06 | 10.63 | 7.32 | 21.37 |
| GSK plc | 36.48bn | 3.65bn | 66.76bn | 68.63k | 18.53 | 4.14 | 8.39 | 1.83 | 0.7625 | 0.7625 | 7.65 | 3.42 | 0.5289 | 1.51 | 4.54 | 459,412.20 | 6.11 | 6.26 | 9.14 | 9.86 | 72.01 | 70.75 | 11.55 | 15.56 | 0.5801 | 15.02 | 0.5745 | 80.46 | 3.46 | -1.45 | -47.75 | -11.13 | 6.63 | -9.41 |
| CSL Ltd | 13.06bn | 2.36bn | 67.30bn | 30.40k | 28.66 | 4.23 | 20.47 | 5.15 | 8.67 | 8.67 | 48.04 | 58.73 | 0.4021 | 1.25 | 4.30 | 767,727.70 | 7.52 | 9.46 | 9.35 | 11.70 | 51.80 | 53.84 | 18.71 | 20.11 | 0.851 | 9.23 | 0.368 | 46.77 | 11.19 | 11.63 | 20.42 | 6.61 | -0.4207 | 7.26 |
| Chugai Pharmaceutical Co Ltd | 7.09bn | 2.38bn | 67.42bn | 7.78k | 27.77 | 5.97 | -- | 9.51 | 249.23 | 249.23 | 742.64 | 1,158.97 | 0.6054 | 1.39 | 4.57 | 157,125,400.00 | 20.32 | 19.55 | 22.85 | 23.95 | 71.01 | 65.51 | 33.56 | 30.12 | 6.16 | -- | 0.00 | 39.66 | 5.33 | 11.27 | 19.00 | 19.71 | -2.14 | 16.00 |
| Bristol-Myers Squibb Co | 41.08bn | 4.67bn | 84.34bn | 34.10k | 18.04 | 5.62 | 7.24 | 2.05 | 2.66 | 2.66 | 23.44 | 8.54 | 0.4976 | 4.27 | 5.12 | 1,396,950.00 | 5.68 | 0.6536 | 7.69 | 0.8175 | 74.69 | 76.63 | 11.41 | 1.52 | 1.17 | 7.39 | 0.7402 | 678.24 | 7.32 | 13.06 | -211.50 | -- | 8.34 | 7.91 |
| Sanofi SA | 45.17bn | 6.22bn | 102.57bn | 84.59k | 16.82 | 1.41 | 13.14 | 2.27 | 4.97 | 5.03 | 36.14 | 59.09 | -- | -- | -- | 533,959.10 | -- | 6.12 | -- | 7.54 | 70.94 | 69.23 | 13.59 | 17.97 | 0.688 | 26.88 | 0.2205 | 59.37 | 6.41 | 3.31 | 8.57 | 14.00 | 12.32 | 4.47 |
| Vertex Pharmaceuticals Inc | 9.57bn | -852.80m | 102.59bn | 6.10k | -- | 7.22 | -- | 10.72 | -3.88 | -3.88 | 42.86 | 64.20 | 0.4744 | 1.43 | 6.17 | 1,819,623.00 | -4.23 | 14.06 | -5.04 | 16.67 | 86.03 | 87.35 | -8.91 | 26.28 | 2.29 | -- | 0.0067 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Gilead Sciences Inc | 24.78bn | 5.14bn | 116.71bn | 17.60k | 23.01 | 7.07 | 15.49 | 4.71 | 4.73 | 4.73 | 22.79 | 15.39 | 0.5098 | 3.45 | 6.35 | 1,632,671.00 | 10.58 | 5.26 | 13.63 | 6.38 | 78.29 | 78.47 | 20.76 | 12.54 | 1.23 | 7.80 | 0.5667 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Pfizer Inc | 53.87bn | 6.78bn | 120.51bn | 81.00k | 17.83 | 1.55 | 9.45 | 2.24 | 1.38 | 1.38 | 10.95 | 15.89 | 0.2911 | 1.46 | 5.47 | 771,148.10 | 3.68 | 7.45 | 4.49 | 9.43 | 74.57 | 69.10 | 12.64 | 20.37 | 0.9604 | 12.26 | 0.4066 | 64.22 | 6.84 | 9.10 | 275.82 | -5.27 | 2.32 | 3.13 |
| Amgen Inc | 29.43bn | 5.12bn | 138.30bn | 28.00k | 27.22 | 25.84 | 13.90 | 4.70 | 10.96 | 10.96 | 63.05 | 11.54 | 0.3743 | 1.59 | 4.58 | 1,218,786.00 | 6.51 | 8.43 | 8.50 | 10.66 | 64.07 | 72.81 | 17.39 | 21.90 | 0.878 | 7.06 | 0.9024 | 71.37 | 18.57 | 7.43 | -39.11 | -12.21 | 12.14 | 9.18 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Jul 2025 | 42.59m | 3.45% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 23.42m | 1.90% |
| Dodge & Coxas of 31 Dec 2023 | 22.51m | 1.83% |
| Capital Research & Management Co. (World Investors)as of 02 Jul 2025 | 20.84m | 1.69% |
| Amundi Asset Management SASU (Investment Management)as of 09 Jul 2025 | 17.98m | 1.46% |
| Capital International Ltd.as of 02 Jul 2025 | 16.06m | 1.30% |
| Geode Capital Management LLCas of 10 Jul 2025 | 15.50m | 1.26% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 15.35m | 1.25% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 12.33m | 1.00% |
| GQG Partners LLCas of 30 Apr 2025 | 8.23m | 0.67% |
